Thyroid hormone receptor
13 drugs Oncology
3
approved indications
13
Approved Drugs
10
Companies
3
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (10 companies)
✓ All 13 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (3 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
KING PHARMS 2 drugs
STEVENS J 2 drugs
IBSA 2 drugs
By Therapeutic Area
Oncology 13 drugs
Drugs by Company PRO
STEVENS J 2 drugs
IBSA 2 drugs
PIRAMAL CRITICAL 1 drug
AbbVie 1 drug
Viatris 1 drug
ALVOGEN 1 drug
GENUS LIFESCIENCES 1 drug
CEDIPROF INC 1 drug
EMD SERONO INC 1 drug
By Therapeutic Area
Oncology 13 drugs
CYTOMEL, LEVOTHYROXINE SODIUM, SYNTHROID, ERMEZA +9 more
Indications Treated
HypothyroidismThyroid CancerHyperthyroidism
All Drugs Targeting Thyroid hormone receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| CYTOMEL | KING PHARMS | 1956 | 3 | Oncology |
| LEVOTHYROXINE SODIUM | PIRAMAL CRITICAL | 2002 | 2 | Oncology |
| SYNTHROID | AbbVie | 2002 | 2 | Oncology |
| ERMEZA | Viatris | 2022 | 2 | Oncology |
| UNITHROID | STEVENS J | 2000 | 2 | Oncology |
| TIROSINT | IBSA | 2006 | 2 | Oncology |
| THYRO-TABS | ALVOGEN | 2002 | 2 | Oncology |
| TIROSINT-SOL | IBSA | 2016 | 2 | Oncology |
| LEVOLET | GENUS LIFESCIENCES | 2003 | 2 | Oncology |
| LEVO-T | CEDIPROF INC | 2002 | 2 | Oncology |
| EUTHYROX | EMD SERONO INC | 2002 | 2 | Oncology |
| LEVOXYL | KING PHARMS | 2001 | 2 | Oncology |
| THYQUIDITY | STEVENS J | 2020 | 2 | Oncology |